N4F. PILOT PROJECTS We typically aim to provide catalytic funding for two Pilot projects during each grant year. Pilot projects are funded for a period of two years at a level in the range of ~$6oK-9oK direct costs per year. The level depends on the extent of personnel and materials/supplies requirement for gaining preliminary results, and the time period permits assessment of how well the science and investigators integrate into the ongoing Projects or Core. The Pilot projects are selected by the Steering Committee from applications submitted by investigators in the MIT (and Harvard) communities, on the basis of potential for providing powerful new approaches that complement overall program aims. If deemed highly successful in collaborative integration, the Pilot investigator(s) can become regular PIs in the Projects or Core. During the previous grant period, Pilots directed by Ernest Fraenkel and Mike Hemann have done so, with results described in the Progress Report section and plans described in the Research Plans section for their corresponding Project and Core participation. The two Pilots intended for Year 6 of the grant if successfully renewed are presented below.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA112967-08
Application #
8375834
Study Section
Special Emphasis Panel (ZCA1-SRLB-C)
Project Start
2012-04-17
Project End
2015-02-28
Budget Start
2012-04-17
Budget End
2013-02-28
Support Year
8
Fiscal Year
2012
Total Cost
$122,362
Indirect Cost
Name
Massachusetts Institute of Technology
Department
Type
DUNS #
001425594
City
Cambridge
State
MA
Country
United States
Zip Code
02139
Bruno, Peter M; Liu, Yunpeng; Park, Ga Young et al. (2017) A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nat Med 23:461-471
Miller, Miles A; Sullivan, Ryan J; Lauffenburger, Douglas A (2017) Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer. Clin Cancer Res 23:623-629
Werbin, Jeffrey L; Avendaño, Maier S; Becker, Verena et al. (2017) Multiplexed Exchange-PAINT imaging reveals ligand-dependent EGFR and Met interactions in the plasma membrane. Sci Rep 7:12150
Oudin, Madeleine J; Barbier, Lucie; Schäfer, Claudia et al. (2017) MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer. Mol Cancer Ther 16:143-155
Carmona, G; Perera, U; Gillett, C et al. (2016) Lamellipodin promotes invasive 3D cancer cell migration via regulated interactions with Ena/VASP and SCAR/WAVE. Oncogene 35:5155-69
Zhao, Boyang; Sedlak, Joseph C; Srinivas, Raja et al. (2016) Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution. Cell 165:234-246
Gosline, Sara J C; Gurtan, Allan M; JnBaptiste, Courtney K et al. (2016) Elucidating MicroRNA Regulatory Networks Using Transcriptional, Post-transcriptional, and Histone Modification Measurements. Cell Rep 14:310-9
Pirhaji, Leila; Milani, Pamela; Leidl, Mathias et al. (2016) Revealing disease-associated pathways by network integration of untargeted metabolomics. Nat Methods 13:770-6
Tape, Christopher J; Ling, Stephanie; Dimitriadi, Maria et al. (2016) Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation. Cell 165:910-20
Oudin, Madeleine J; Miller, Miles A; Klazen, Joelle A Z et al. (2016) MenaINV mediates synergistic cross-talk between signaling pathways driving chemotaxis and haptotaxis. Mol Biol Cell 27:3085-3094

Showing the most recent 10 out of 217 publications